Such an approach could be more specific for Alzheimer's than symptoms-based diagnoses while also allowing for earlier detection and treatment of the condition.
Evogen launched a clinical trial to further validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures.
The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
